As the result of various mechanisms (including the inhibition of T cell priming), TIGIT inhibits both T cells and NK cells, leading to an impaired anti-tumor immune response and making it an interesting factor in the context of cancer immunotherapy [17] (Figure 1). This evidence concerns the gene TIGIT and neoplasm.